Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT7 | O95251 | 20/20 | 0.71 |
| ▸ | KAT6A | Q92794 | 20/20 | 0.71 |
| ▸ | KAT6B | Q8WYB5 | 10/20 | 0.70 |
| ▸ | KAT5 | Q92993 | 10/20 | 0.70 |
| ▸ | KAT8 | Q9H7Z6 | 10/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30680839 | 1.00 | KAT7 (0.71) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL26969646 | 0.89 | KAT7 (0.68) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL30680827 | 0.87 | KAT7 (0.64) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL26969644 | 0.87 | KAT7 (0.64) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL30680852 | 0.86 | KAT7 (0.69) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL26969640 | 0.86 | KAT7 (0.69) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL30680822 | 0.85 | KAT7 (0.74) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL26969652 | 0.85 | KAT7 (0.74) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL27345697 | 0.84 | KAT7 (0.53) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL22817349 | 0.83 | KAT7 (1.00) | KAT7KAT6AKAT6BKAT5KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | PRELUDE THERAPEUTICS, INCORPORATED | 2023-12-28 | — | — | US | disclosed |
| WO-2023245150-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023245150-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | KAT6A, KAT6B, KAT2A | KAT7 4/4885KAT6A 1/4885KAT6B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.